Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli;Síndrome urémico hemolítico inducido por Escherichia coli enterohemorrágica

Archivos Argentinos de Pediatria

Volumn 106, Issue 5, 2008, Pages 435-442

  Ibarra, Cristina ^a   Goldstein, Jorge ^a   Silberstein, Claudia ^a   Zotta, Elsa ^a   Belardo, Marcela ^b   Repetto, Horacio A ^c  

^a Laboratorio de Fisiopatogenia

^b Hospital Nacional Prof Alejandro Posadas ^*

^c HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56749140985     PISSN: 03250075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Gasser C, Gautier E, Steck A, et al. Hämolytisch-urämische Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen-Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
2. Gianantonio C, Vitacco M, Mendiakarzu F, Rutty A. The hemolytic-uremic syndrome. J Pediatr 1964; 64: 478-491.
3. Scully RE, Mark EJ, McNeely WF, et al. Case records of the Massachusetts General Hospital. N Engl J Med 1995; 336: 1587-1594.
4. Rivas M, Miliwebsky E, Chinen I, et al. The Case-Control. Study Group: Characterization and epidemiologic subtyping of Shiga toxin producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathg Dis 2006, 3:88-96.
5. Kaper JB, O'Brien AD. (Eds.). Escherichia coli, 0157:H7 and other Shiga toxin-producing E coli. Washington, DC: American Society Microbiology Press, 1998.
6. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142-201.
7. Cordovéz A, Prado V, Maggi L, et al. Enterohemorragic Escherichia coli associated with hemolytic uremic syndrome in Chilean children. J Clin Microbiol 1992; 30:2153-2157.
8. Rivas M, Miliwebsky E, Chinen I, et al. The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmisión. Medicina (B Aires) 2006; 66(Suppl 3):27-32.
9. Comité de Nefrología de la Sociedad Argentina de Pediatría: Incidencia del Síndrome Urémico Hemolítico (SUH) en la República Argentina. Arch Argent Pediatr 1995; 93:407-11.
10. Exeni R. Síndrome urémico hemolítico. Arch Latin Nefr Ped 2001; 1:35-56.
11. Repetto HA. Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. Kidney Int Suppl 2005; 97:S102-106.
12. Cobeñas CJ, Alconcher LF, Spizzirri AP, Rahman RC. Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis. Pediatr Nephrol 2007; 22:1343-1347.
13. Caletti MG, Petetta D, Jaitt M, et al. Hemolytic uremic syndrome (HUS): medical and social costs of treatment. Medicina (B Aires) 2006; 66(Suppl 3):22-26.
14. Cobbold R, Desmarchelier P. A longitudinal study of Shigatoxigenic Escherichia coli (STEC) prevalence in three Australian dairy herd. Vet Microbiol 2000; 71:125-137.
15. Meichtri L, Miliwebsky E, Gioffre A, et al. Shiga toxin-producing Escherichia coli in healthy young beef steers from Argentina: prevalence and virulence properties. I. J Food Microbiol 2004; 96:189-198.
16. Mercado EC, Gioffre A, Rodríguez SM, et al. Non-0157 Shiga toxin-producing Escherichia coli isolated from diarrhoeic calves in Argentina. J Vet Med 2004; 51:82-88.
17. Rivas M, Caletti MG, Chinen I, et al. Home-prepared hamburger and sporadic hemolytic uremic syndrome, Argentina. Emerg Infect Dis 2003; 9:1184-6.
18. Jacewicz MS, Acheson DW, Mobassaleh M, et al. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest 1995; 96:1328-1335.
19. Melton-Celsa AR, Kokai-Kun JF, O'Brien AD. Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the contexto of the appropiate B pentamer. Mol Microbiol 2002; 43:207-215.
20. 5 toxin that targets the endoplasmic reticulum. J Inf Dis 2007; 196:1093-1101.
21. Sandvig K, Van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev 1996; 76:949-966.
22. Morinaga N, Yahiro K, Matsuura G, et al. Two distinct cytotoxic activities of subtilase cytotoxin produced by Shigatoxigenic Escherichia coli. Infect Immun 2007; 78:488-496.
23. Endo Y, Tsurugi K, Yutsudo T, et al. Site of action of a Vero toxin (VT2) from E coli 0157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171:335-337.
24. Smith WE, Kane AK, Campbell ST, et al. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003; 71:1497-1504.
25. 5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BIP. Nature 2006; 443:548-552.
26. Hendershot LM. The ER chaperone BIP is a master regulador of ER function. Mt Sinai J Med 2004; 71:289-297.
27. Pistone Creydt V, Silberstein C, Zotta E, Ibarra C. Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. Microbe Infec 2006, 8:410-419.
28. Taga S, Carlier K, Mishal Z, et al. Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood 1997; 90:2757-67.
29. Pistone Creydt V, Martín F, Fernández Miyakawa M, et al. Shiga toxin 2B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Brazilian J Med Biol Res 2004; 37:799-808.
30. Silberstein C, Pistone Creydt V, Gerhardt E, et al. Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2. Pediatr Nephrol 2008, Jul 8. DOI:10.1007/s00467-008-0896-9.
31. Römer W, Berland L, Chambon V, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007; 450:670-675.
32. Repetto HA. Personal comunication of a review of 104 patients in the Hospital Nacional "Prof. Alejandro Posadas", Buenos Aires, Argentina, 2007.
33. Fraser ME, Fujinaga M, Cherney MM, et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli 0157:H7. J Biol Chem 2004; 279:27511-27517.
34. Soltyk AM, MacKenzie CR, Wolski VM, et al. A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. J Biol Chem 2002; 277:5351-5359.
35. Watanabe M, Igai K, Matsuoka K, et al. Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infect Immun 2006; 74:1984-1988.
36. Schweppe CH, Bielaszewska M, Pohlentz G, et al. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J 2008; 25:291-304.
37. Hanashima T, Miyake M, Yahiro K, et al. Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells. Microb Pathog 2008; 45:124-133.
38. Garred O, Van Deurs B, Sandvig K. Furin-inducede cleavage and activation of Shiga toxin. J Biol Chem 1995; 270:10817-10821.
39. Lea N, Lord JM, Roberts LM. Proteolityc cleavage of the A subunit is essentials for maximal cytotoxicity of Escherichia coli 0157:H7 Shiga-like toxin-1. J Microbiol 1999; 145:999-1004.
40. Philpott DJ, Ackerley CA, Kilissan AJ, et al. Traslocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am J Physiol 1997; 273:G1349-G1358.
41. Schüller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damages in organ culture. Cell Microbiol 2004; 6:289-301.
42. Núñez P, Pistone Creydt V, Bibini M, Ibarra C. Acción citotóxica de la toxina Shiga tipo 2 (Stx2) dependiente e independiente de Gb3 en modelos celulares de epitelio intestinal humano. Medicina (B Aires) 2005; 65:86. [Abstract].
43. Acheson D, Moore R, De Breucker S, et al. Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun 1996; 64:3294-3300.
44. Imai Y, Fukui T, Kurohane K, et al. Restricted expression of Shiga toxin binding sites on mucosal epithelium of mouse distal colon. Infect Immun 2003; 71:985-990.
45. Fiorito P, Burgos J, Fernández-Miyakawa M, et al. Effect of Shiga toxin 2 on water and ion transport in the human colon in vitro. Dig Dis Sc 2000; 45:480-486.
46. Slutsker L, Ries AA, Greene KD, et al. Escherichia coli 0157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505-513.
47. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69:6148-55.
48. Lidgwood CA. Verotoxin-binding in human renal section. Nephron 1994; 66:21-28.
49. Ray PE, Liu XH. Pathogenesis of shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 2001; 16:823-839.
50. Richardson SE, Karmali MA, Becker LE, Smith CR. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing E coli. Hum Pathol 1988; 19:1102-1108.
51. Kaplan BS. Shiga toxin induced tubular injury in hemolytic uremia sindrome. Kidney Int 1998; 54:648-649.
52. Exeni R, Grimold I, Amore A, Antonuccio M. Función tubular en niños con SUH. Arch Argent Pediatr 1977; 75:149-153.
53. Takeda T, Dohi S, Igarashi T, et al. Impairment by verotoxin of tubular function contributes to the renal damage seen in haemolytic uremic syndrome. J Infect 1993; 27:339-341.
54. Hughes AK, Stricklett PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubules cells. Kidney Int 1998; 54:426-437.
55. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998; 66:636-644.
56. Taguchi T, Uchida H, Kiyokawa N, et al. Verotoxins induce apoptosis in human renal tubular epithelium derived. Kidney Int 1998; 53:1681-1688.
57. Karpman D, Andreasson A, Thysell H, et al. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995; 9:694-699.
58. Kiyokawa N, Taguchi T, Mori T, et al. Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxin 1 and 2. J Infect Dis 1998; 178:178-184.
59. Cherla RP, Sang-Yun L, Tesh VL. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003; 228:159-166.
60. Taylor FB Jr, Tesh VL, DeBault L, Li A, et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154:1285-1299.
61. Zotta E, Lago N, Ochoa F, et al. Development of an experimental hemolytic uremic syndrome in rats. Pediatr Nephrol 2008; 23:559-567.
62. Brando RJF, Miliwebsky E, Bentancor L, et al. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin Exp Immunol 2008, Jun 10. DOI:10.1111/j.1365-2249. 2008.03698.x.
63. Fujii J, Kita T, Yoshida S, et al. Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli 0157:H- in mitomycin-treated mice. Infect Immun 1994; 62:3447-3453.
64. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun 1996; 64:5053-5060.
65. Fujii J, Kinoshita Y, Yamada Y, et al. Neurotoxicity of intrathecal Shiga toxin 2 and protection by intrathecal injection of anti-Shiga toxin 2 antiserum in rabbits. Microb Pathog 1998; 25:139-46.
66. Goldstein J, Loidl CF, Pistone Creydt V, et al. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res 2007; 1161:106-115.
67. Boccoli J, Loidl CF, López-Costa JJ, et al. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res 2008. DOI: 10.1016/j.brainres.2008.07. 052.
68. Iijima, K, Kamioka I, Nozu K. Management of diarrhea-associated hemolytic uremia síndrome in children. Clin Exp Nephrol 2008; 12:16-19.
69. Carey CM, Kostrzynska M, Ojha S, Thompson S. The effect of probiotics and organic acids on Shiga-toxin 2 gene expresion in enterohemorrhagic Escherichia coli 0157:H7. J Micobiol Methods 2008; 73:125-132.
70. Hugo AA, Kakisu E, De Antoni GL, Pérez PF. Lactobacilli antagonize biological effects of enterohaemorrhagic Escherichia coli in vitro. Lett Appl Microbiol 2008; 46:613-619.
71. Pedersen MG, Hansen C, Riise E, et al. Subtype-specific Suppression of released Shiga toxin 2 from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol 2008. DOI:10.1128/JCM.00871-08.
72. Vilte DA, Larzábal M, Cataldi AA, Mercado EC. Bovine colostrum contains IgG antibodies against Intimin, EspA and EspB proteins, and inhibits the hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli. Clin Vaccine Immunol 2008; 15:1208-1213.
73. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337-44.
74. Watanabe M, Igai K, Matsuoka K, et al. Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infect Immun 2006; 74:1984-1988.
75. Neri P, Tokoro S, Yokoyama S, et al. Monovalent Gb3-/ Gb2-derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent. Biol Pharm Bull 2007; 30:1697-1701.
76. Capozzo AVE, Pistone Creydt V, Dran G, et al. Development of genetic vaccines against hemolytic uremic syndrome (HUS). Infect Immunol 2003; 71:3971-3978.
77. Smith MJ, Teel LD, Carvalho HM, et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006; 24:4122-129.
78. Zhu C, Yu J, Yang Z, et al. Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin B subunit. Clin Vaccine Immunol 2007; 15:359-66.
79. Okuda T, Tokuda N, Numata S-I, et al. Targeted disruption of Gb3/DC77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 2006; 281:10230-10235.
80. Belardo MB, Pecheny M, Ibarra C. Resumen presentado en el 11° Congreso Argentino de Pediatría Social: 1-4 de octubre, Ciudad de Buenos Aires, 2008.